A Phase 2 interventional study of Abemaciclib in Metastatic Castration-Resistant Prostate Cancer, sponsored by Eli Lilly and Company. Completed at 14 sites in 3 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-25.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing abemaciclib in Prostatic Neoplasms — 1 open to participants now, 3 under way, 2 of them phase 3. abemaciclib · Prostatic Neoplasms.
Among the 10 studies testing abemaciclib in Prostatic Neoplasms, this one is the 3rd largest by enrollment, is one of 3 that started in 2021, is one of 5 in phase 2, and was the 4th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →1 of the 10 studies testing abemaciclib in Prostatic Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Vadim S Koshkin · Sites in United States
Ages 18+
By country, each count listing its studies:
abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, abemaciclib is the treatment under test here. Read study by study →
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 2
First in 2018; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 44 is below the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 15 across the 10 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 7 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
20 studies in Prostatic Neoplasms by Eli Lilly and Company: 2 open now, 8 under way, 3 of them phase 3. Of 11 finished, 10 (91%) have results posted.
Among the 20 studies in Prostatic Neoplasms by Eli Lilly and Company, this one is the 17th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2021, is one of 9 in phase 2, and was the 12th registered.
Eli Lilly and Company’s Prostatic Neoplasms studies by the year they started, since 2007.
1 of the studies testing abemaciclib in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05113537Vadim S KoshkinAbemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing abemaciclib in Prostatic Neoplasms, from their registry updates:
Among Eli Lilly and Company’s 20 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study will evaluate how safe and effective abemaciclib is when given to participants whose metastatic prostate cancer progresses after they had received several previous treatments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 200 mg abemaciclib administered orally twice daily on a continuous dosing schedule (28-day cycle) until symptomatic and/or radiographic progression, unacceptable toxicity, or until another discontinuation criterion is met.
Drug: Abemaciclib
Administered orally
Also known as: LY2835219
Percentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR])
ORR is defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) in soft tissue per response evaluation criteria in solid tumors (RECIST) version 1.1 and do not have concurrent bone progression per Prostate Cancer Clinical Trials Working Group 3 (PCWG3), as assessed by the investigator. ORR = (participants with confirmed CR and no bone progression) + (participants with confirmed PR and no bone progression) x 100 / all treated participants.
Time frame: From Date of First Dose until Objective Progression (Up To 12.8 Months)
Radiographic Progression-Free Survival (rPFS)
The rPFS time is measured from the date of first dose to the earliest date of investigator-assessed radiographic progression per RECIST 1.1 for soft tissue and PCWG3 criteria for bone, or death from any cause, whichever occurred first. Participants who have neither progressed nor died will be censored at the day of their last radiographic tumor assessment (if available) or date of first dose if no post initiation (i.e., postbaseline) radiographic assessment is available.
Time frame: From Date of First Dose until Objective Progression or Death from Any Cause (Up To 12.8 Months)
Overall Survival (OS)
OS time is measured from the date of first dose to the date of death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data were censored on the last date the participant was known to be alive.
Time frame: From Date of First Dose until Date of Death from Any Cause (Up To 28 Months)
Duration of Response (DoR)
DoR is measured only for confirmed responders (participants with a confirmed soft tissue best overall response of CR or PR per RECIST 1.1 no concurrent bone progression per PCWG3). It is measured from the date of first evidence of soft tissue CR or PR to the earliest date of investigator-assessed radiographic progression or death from any cause, whichever is earlier.
Time frame: CR or PR to Disease Progression or Death Due to Any Cause (Up to 12 Months)
Percentage of Participants Achieving CR, PR or Stable Disease (SD) (Disease Control Rate [DCR])
The DCR is defined as the percentage of participants with confirmed soft tissue best overall response of CR, PR, or stable disease (SD) per RECIST 1.1, and do not have concurrent bone disease progression per PCWG3.
Time frame: From Date of First Dose until Measured Progressive Disease or Death Due to Any Cause (Up To 12.8 Months)
Time to Prostate-Specific Antigen (PSA) Progression
Time to PSA progression is defined as the time from the date of treatment initiation to the date of first observation of PSA progression. The PSA progression is defined as a greater than or equal to (\>=) 25 percentage (%) increase and an absolute increase of \>=2 nanogram/milliliter (ng/mL) above the nadir (or baseline value if baseline is the smallest on study), which is confirmed by a second value obtained 3 or more weeks later.
Time frame: From Date of First Dose until Confirmed PSA Progression (Up To 12.8 Months)
Percentage of Participants Who Achieved Prostate-Specific Antigen (PSA) Response (PSA Response Rate)
The PSA response rate is defined as the percentage of participants with a reduction in PSA level ≥50% from baseline, confirmed with a second assessment conducted at least 3 weeks later.
Time frame: From Date of First Dose until Confirmed PSA Progression (Up To 12.8 Months)
Time to Symptomatic Progression
Time to symptomatic progression is defined as the time from first dose to any of the following (whichever occurred earlier): 1) symptomatic skeletal event, defined as symptomatic fracture, surgery, or radiation to bone, or spinal cord compression; 2) pain progression or worsening of disease-related symptoms requiring initiation of a new systemic anticancer therapy; and 3) development of clinically significant symptoms due to locoregional tumor progression requiring surgical intervention or radiation therapy. For participants who were not known to have symptomatic progression at the time of data analysis, data were censored on the last date at which no symptomatic progression was indicated.
Time frame: From Date of First Dose until Symptomatic Progression (Up to 12.8 Months)
Pharmacokinetics (PK): Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib
PK: Cmax,ss of abemaciclib is reported. The cycle length was 28 days.
Time frame: Cycle (C) 1 Day (D) 1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose
PK: Minimum/Trough Concentration at Steady State (Cmin,ss) of Abemaciclib
PK: Cmin,ss of abemaciclib is reported.
Time frame: C1 D1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose
PK: Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib Metabolites (Total Active Species)
PK: Cmax,ss of abemaciclib metabolites (Total Active Species) is reported.
Time frame: C1 D1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose
PK: Minimum/Trough Concentration at Steady State (Cmin,ss) of Abemaciclib Metabolites (Total Active Species)
PK: Cmin,ss of abemaciclib metabolites (Total Active Species) is reported.
Time frame: C1 D1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose
Percentage of Participants With Expression of Ki-67 Proliferation Marker by Immunohistochemistry (IHC)
Percentage of participants with expression of Ki-67 proliferation marker at baseline by immunohistochemistry. Baseline expression of the Ki-67 proliferation marker was evaluated by IHC utilizing a 20% or higher score to define high Ki-67 expression. The percentage of Ki-67 positive cells was defined by the number of non-apoptotic tumor cells with unequivocal brown nuclear staining (intensities ≥1 using a 0-3 scale) over the total number of non-apoptotic tumor cells. Unit of Measure is percentage of participants with low or high baseline Ki-67 expression.
Time frame: Baseline
| Milestone | 200 Milligram (mg) Abemaciclib Twice Daily |
|---|---|
| Started | 44 |
| Received at least one dose of study drug | 44 |
| Completed | 31 |
| Not completed | 13 |
| Withdrew: Off treatment on post-treatment-discontinuation follow-up | 3 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Sponsor decision | 2 |
ORR is defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) in soft tissue per response evaluation criteria in solid tumors (RECIST) version 1.1 and do not have concurrent bone progression per Prostate Cancer Clinical Trials Working Group 3 (PCWG3), as assessed by the investigator. ORR = (participants with confirmed CR and no bone progression) + (participants with confirmed PR and no bone progression) x 100 / all treated participants.
| percentage of participants | 200 mg Abemaciclib Twice Daily |
|---|---|
| Percentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR]) | 6.8 (0.0 to 14.3) |
The rPFS time is measured from the date of first dose to the earliest date of investigator-assessed radiographic progression per RECIST 1.1 for soft tissue and PCWG3 criteria for bone, or death from any cause, whichever occurred first. Participants who have neither progressed nor died will be censored at the day of their last radiographic tumor assessment (if available) or date of first dose if no post initiation (i.e., postbaseline) radiographic assessment is available.
| months | 200 mg Abemaciclib Twice Daily |
|---|---|
| Radiographic Progression-Free Survival (rPFS) | 2.7 (1.9 to 3.7) |
OS time is measured from the date of first dose to the date of death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data were censored on the last date the participant was known to be alive.
| months | 200 mg Abemaciclib Twice Daily |
|---|---|
| Overall Survival (OS) | 8.38 (5.62 to 12.69) |
DoR is measured only for confirmed responders (participants with a confirmed soft tissue best overall response of CR or PR per RECIST 1.1 no concurrent bone progression per PCWG3). It is measured from the date of first evidence of soft tissue CR or PR to the earliest date of investigator-assessed radiographic progression or death from any cause, whichever is earlier.
| months | 200 mg Abemaciclib Twice Daily |
|---|---|
| Duration of Response (DoR) | NA (3.88 to 11.18) |
The DCR is defined as the percentage of participants with confirmed soft tissue best overall response of CR, PR, or stable disease (SD) per RECIST 1.1, and do not have concurrent bone disease progression per PCWG3.
| percentage of participants | 200 mg Abemaciclib Twice Daily |
|---|---|
| Percentage of Participants Achieving CR, PR or Stable Disease (SD) (Disease Control Rate [DCR]) | 45.5 (30.7 to 60.2) |
Time to PSA progression is defined as the time from the date of treatment initiation to the date of first observation of PSA progression. The PSA progression is defined as a greater than or equal to (\>=) 25 percentage (%) increase and an absolute increase of \>=2 nanogram/milliliter (ng/mL) above the nadir (or baseline value if baseline is the smallest on study), which is confirmed by a second value obtained 3 or more weeks later.
| months | 200 mg Abemaciclib Twice Daily |
|---|---|
| Time to Prostate-Specific Antigen (PSA) Progression | 6.5 (3.2 to NA) |
The PSA response rate is defined as the percentage of participants with a reduction in PSA level ≥50% from baseline, confirmed with a second assessment conducted at least 3 weeks later.
| percentage of participants | 200 mg Abemaciclib Twice Daily |
|---|---|
| Percentage of Participants Who Achieved Prostate-Specific Antigen (PSA) Response (PSA Response Rate) | 4.6 |
Time to symptomatic progression is defined as the time from first dose to any of the following (whichever occurred earlier): 1) symptomatic skeletal event, defined as symptomatic fracture, surgery, or radiation to bone, or spinal cord compression; 2) pain progression or worsening of disease-related symptoms requiring initiation of a new systemic anticancer therapy; and 3) development of clinically significant symptoms due to locoregional tumor progression requiring surgical intervention or radiation therapy. For participants who were not known to have symptomatic progression at the time of data analysis, data were censored on the last date at which no symptomatic progression was indicated.
| months | 200 mg Abemaciclib Twice Daily |
|---|---|
| Time to Symptomatic Progression | 4.1 (3.7 to NA) |
PK: Cmax,ss of abemaciclib is reported. The cycle length was 28 days.
| nanogram per milliliter (ng/ mL) | 200 mg Abemaciclib Twice Daily |
|---|---|
| Pharmacokinetics (PK): Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib | 223 ± 47 |
PK: Cmin,ss of abemaciclib is reported.
| ng/mL | 200 mg Abemaciclib Twice Daily |
|---|---|
| PK: Minimum/Trough Concentration at Steady State (Cmin,ss) of Abemaciclib | 176 ± 37 |
PK: Cmax,ss of abemaciclib metabolites (Total Active Species) is reported.
| micromolar per liter (µmol/L) | 200 mg Abemaciclib Twice Daily |
|---|---|
| PK: Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib Metabolites (Total Active Species) | 1.7 ± 79 |
PK: Cmin,ss of abemaciclib metabolites (Total Active Species) is reported.
| µmol/L | 200 mg Abemaciclib Twice Daily |
|---|---|
| PK: Minimum/Trough Concentration at Steady State (Cmin,ss) of Abemaciclib Metabolites (Total Active Species) | 1.5 ± 80 |
Percentage of participants with expression of Ki-67 proliferation marker at baseline by immunohistochemistry. Baseline expression of the Ki-67 proliferation marker was evaluated by IHC utilizing a 20% or higher score to define high Ki-67 expression. The percentage of Ki-67 positive cells was defined by the number of non-apoptotic tumor cells with unequivocal brown nuclear staining (intensities ≥1 using a 0-3 scale) over the total number of non-apoptotic tumor cells. Unit of Measure is percentage of participants with low or high baseline Ki-67 expression.
| Percentage of participants | 200 mg Abemaciclib Twice Daily |
|---|---|
| Low baseline Ki-67 expression | 25.8 |
| High baseline Ki-67 expression | 74.2 |
Collected over Baseline Up to 28 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 200 mg Abemaciclib Twice Daily | 31/44 (70.5%) | 18/44 (40.9%) | 42/44 (95.5%) |
| Event | 200 mg Abemaciclib Twice Daily |
|---|---|
| PyrexiaGeneral disorders | 3/44 |
| Renal failureRenal and urinary disorders | 3/44 |
| AnaemiaBlood and lymphatic system disorders | 2/44 |
| Blood creatinine increasedInvestigations | 2/44 |
| Myocardial infarctionCardiac disorders | 1/44 |
| DiplopiaEye disorders | 1/44 |
| DiarrhoeaGastrointestinal disorders | 1/44 |
| HaemoperitoneumGastrointestinal disorders | 1/44 |
| General physical health deteriorationGeneral disorders | 1/44 |
| PainGeneral disorders | 1/44 |
| Event | 200 mg Abemaciclib Twice Daily |
|---|---|
| DiarrhoeaGastrointestinal disorders | 36/44 |
| AstheniaGeneral disorders | 24/44 |
| Decreased appetiteMetabolism and nutrition disorders | 24/44 |
| NauseaGastrointestinal disorders | 21/44 |
| AnaemiaBlood and lymphatic system disorders | 16/44 |
| VomitingGastrointestinal disorders | 16/44 |
| NeutropeniaBlood and lymphatic system disorders | 13/44 |
| ConstipationGastrointestinal disorders | 9/44 |
| Blood creatinine increasedInvestigations | 7/44 |
| Back painMusculoskeletal and connective tissue disorders | 7/44 |
All participants who received at least one dose of the study drug.
| Age, Continuous(years) | 200 mg Abemaciclib Twice Daily |
|---|---|
| Mean | 68.3 ± 9.2 |
| Sex: Female, Male(Participants) | 200 mg Abemaciclib Twice Daily |
|---|---|
| Female | 0 |
| Male | 44 |
| Ethnicity (NIH/OMB)(Participants) | 200 mg Abemaciclib Twice Daily |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 3 |
| Unknown or Not Reported | 41 |
| Race (NIH/OMB)(Participants) | 200 mg Abemaciclib Twice Daily |
|---|---|
| American Indian or Alaska Native | 3 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 27 |
| More than one race | 0 |
| Unknown or Not Reported | 14 |
| Region of Enrollment(participants) | 200 mg Abemaciclib Twice Daily |
|---|---|
| France | 14 |
| Spain | 27 |
| United States | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jan 2021 to primary completion in Apr 2022, 15 months.
Results were first posted in May 2023, 1 year after primary completion.
Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 15 months is below that.
Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abemaciclib